A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
- Citation:
- Clin Genitourin Cancer vol 6 (2) 110-6
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA04326, CA04457, CA07968, CA11789, CA16450, CA31946, CA31983, CA32291, CA33601, CA35279, CA35421, CA41287, CA45389, CA45418, CA45808, CA47559, CA47642, CA60138, CA74811, CA77298, CA77406, CA77440, CA77597, CA77658
- Corr. Author:
- Authors:
- Nancy A Dawson Susan Halabi San-San Ou David D Biggs Anne Kessinger Nicholas Vogelzang Gerald H Clamon David M Nanus W Kevin Kelly Eric J Small
- Networks:
- Study
- CALGB-90004
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Aged, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Administration Schedule, Drug Resistance, Neoplasm, Estramustine, Humans, Male, Middle Aged, Prostate-Specific Antigen, Prostatic Neoplasms, Sulindac, Survival Analysis, Taxoids, Thromboembolism